Quavo Fraud & Disputes Named 'Best Dispute Management & Resolution Solution' by Fintech Futures
WILMINGTON, Del., June 03, 2025 (GLOBE NEWSWIRE) -- Quavo Fraud & Disputes has been recognized as the winner of the 'Best as-a-Service Solution – Dispute Management & Resolution' category at the 2025 Banking Tech Awards USA, hosted by Fintech Futures. The award honors Quavo's QFD® platform, an end-to-end SaaS solution purpose-built to transform and streamline dispute management for financial institutions and deliver a seamless experience for accountholders.
This prestigious accolade underscores Quavo's continued commitment to innovation in fraud and dispute resolution, enabling financial institutions to reduce operational costs, ensure regulatory compliance, and deliver trust-building experiences that foster loyalty among accountholders.
'This award is a testament to our team's relentless focus on customer experience, compliance, and AI advancements,' said Chief Product Officer and Co-Founder, David Chmielewski. 'By building QFD® with intelligence from the ground up, we've created a platform that adapts to change, scales with demand, and earns trust with every interaction.'
Quavo's flagship solution, QFD®, is an AI-powered platform built exclusively for financial institutions to automate and streamline the entire dispute lifecycle. The platform delivers a compliant, scalable, and highly automated experience, enabling financial institutions to act quickly and accurately while empowering consumers with transparency and control.
Now in its fourth year, the Banking Tech Awards USA celebrates the most innovative and impactful achievements across banking and fintech. This year's competition featured more than 80 leading banks, credit unions, and technology providers across 40+ categories, including technology excellence, leadership, and project implementation.
About Quavo, Inc.
Quavo is a leading technology partner and strategic advisor, helping financial institutions (FIs) build trust-driven customer relationships through faster, more transparent dispute resolutions. Our mission is to restore financial trust by simplifying fraud and disputes. Quavo's award-winning technology automates the entire dispute lifecycle, from intake to resolution. FIs can pair this end-to-end solution with our expert-led back-office investigation team in one turnkey managed service. Scalable for institutions of all sizes, Quavo's solutions reduce losses, ensure compliance, and enhance customer loyalty. Learn more at www.quavo.com.
Media Contact:
Julia Lum
PR & Events Specialist
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year. David Veitch, Basilea's Chief Executive Officer, stated: 'This milestone payment for the Asia Pacific region, including China, reflects the strong and growing global demand for novel antifungal therapies. Continued growth of Cresemba, particularly in China, where uptake has been especially robust, reinforces its significant clinical value for patients facing life-threatening infections. We congratulate our partner Pfizer for their ongoing commitment to making Cresemba available to patients in need.' The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region. Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between January and December 2024 amounted to USD 562 million, a 19 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1 About Cresemba® (isavuconazole) Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This press release can be downloaded from References IQVIA Analytics Link, December 2024. In-market sales reported as moving annual total (MAT) in US dollar. European Public Assessment Report (EPAR) Cresemba: [Accessed: June 04, 2025] Summary of Product Characteristics (SmPC) Cresemba: [Accessed: June 04, 2025] Full US prescribing information: [Accessed: June 04, 2025] The registration status and approved indications may vary from country to country. Attachment Press release (PDF)
Yahoo
an hour ago
- Yahoo
Point and Funds Managed by Blue Owl Capital Close Oversubscribed $248 Million Home Equity Investment Rated Securitization
Point completes its fourth rated securitization, securing over $2 Billion in orders from investors, signaling further maturation of the home equity investment asset class Palo Alto, California, June 05, 2025 (GLOBE NEWSWIRE) -- Point, the leading home equity investment platform making homeownership more valuable and accessible, and funds managed by Blue Owl Capital ('Blue Owl') announced today that they have completed a rated securitization of Point's Home Equity Investment ('HEI') assets, issuing $248.6 million of rated asset-backed securities (the 'Transaction'). The Transaction is Point's fourth rated securitization and fifth overall. The Transaction closed on May 23, 2025. The issuer, Point Securitization Trust 2025-1, issued $162.2 million of senior class A-1 securities rated A (low) (sf), $35 million of mezzanine class A-2 securities rated BBB (low) (sf), $28.3 million of subordinate class B-1 securities rated BB (low) (sf), and $23.1 million of subordinate class B-2 securities rated B (high) (sf) (retained), all rated by Morningstar DBRS. A portion of the notes were acquired by accounts managed by an affiliate of Blue Owl. The Transaction drew significant interest from both new and repeat institutional investors, resulting in the Transaction being more than 8x oversubscribed. Co-sponsoring the Transaction with a subsidiary of Blue Owl, Point was the originator of all the HEIs in the securitization and will continue to service the assets. 'This past year has been transformative—for Point and for the entire HEI space,' said Eddie Lim, co-founder and CEO of Point. 'Investor demand has never been stronger, and the performance of our deals continues to outperform expectations. Our latest securitization was met with overwhelming enthusiasm, reinforcing that HEIs aren't just gaining traction—they're reshaping how homeowners access equity. We're just scratching the surface of what's possible.' Over the past 18 months, the rated securitization space for HEIs has entered a new phase of maturation. With multiple HEI-backed deals successfully rated, the asset class is seeing increased institutional recognition and investor confidence, with issuance volume doubling and the number of transactions tripling in 2024 alone[1]. According to Finsight[2], HEI-backed deals totaled $936 million across five transactions last year—up significantly from prior years. These transactions have helped set important benchmarks for credit quality, structure, and performance, signaling a shift from emerging to established within the alternative housing finance landscape. 'The Blue Owl Alternative Credit team and Point have a longstanding relationship dating back to 2018, and we are excited to continue our partnership with the Point team,' said Ivan Zinn, Head of Alternative Credit at Blue Owl. 'This marks the second Point transaction that Blue Owl has co-sponsored, and we look forward to doing many more together. The success of this transaction is a testament to the Point platform and validates the thesis that HEIs will continue to be a growing asset class.' Barclays Capital Inc. ('Barclays') was the sole-structuring agent for the issuance. Barclays, Citigroup Global Markets Inc., and Nomura Securities International Inc. were joint bookrunners on the Transaction, and East West Markets, LLC and Cantor Fitzgerald & Co. were co-managers on the Transaction. About Point Point is the leading home equity platform making homeownership more valuable and accessible. Point's flagship product, the Home Equity Investment (HEI), empowers homeowners to unlock their equity to eliminate debt, get through periods of financial hardship, and diversify their wealth – without adding to their monthly expenses. Point has worked with more than 15,000 homeowners, unlocking more than $1.5 billion in home equity. Point's HEI enables investors to access a previously untapped asset class – owner-occupied residential real estate. Founded in 2015 by Eddie Lim, Eoin Matthews, and Alex Rampell, Point is backed by top investors, including Westcap, Andreessen Horowitz, Ribbit Capital, Greylock Partners, Bloomberg Beta, Blue Owl Capital, Alpaca VC, and Prudential. The company is headquartered in Palo Alto, CA. For more information, please visit Blue Owl CapitalAbout Blue Owl: Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With $273 billion in assets under management as of March 31, 2025, we invest across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Assets. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 1,200 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit [1] Source: [2] Source: CONTACT: Amanda Woolley Point 3603191738 awoolley@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
Dr. Reddy's shares surge 4% after company partners with Alvotech to develop and commercialize Biosimilar to Keytruda
By Aman Shukla Published on June 5, 2025, 09:29 IST Shares of Dr. Reddy's Laboratories rose 4% in morning trade after the company announced a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilars. The two companies will co-develop and manufacture a biosimilar version of Keytruda® (pembrolizumab), a blockbuster immunotherapy drug used to treat various cancers. Keytruda® generated global sales of US$29.5 billion in 2024, highlighting the significant market potential for its biosimilar version. Through this partnership, Dr. Reddy's and Alvotech aim to accelerate development timelines and expand access to affordable cancer treatments across international markets. As part of the agreement, both firms will jointly invest in R&D, manufacturing, and regulatory processes. Each partner retains global commercialization rights, with certain market exceptions, allowing for broad market reach while optimizing operational efficiency. Dr. Reddy's Laboratories shares opened at ₹1,264.20 and at the time of writing, surged to an intraday high of ₹1,303.40, matching the day's low at the opening price. The stock is trading near its 52-week high of ₹1,421.49, significantly above its 52-week low of ₹1,020.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
